ABOS | Acumen Pharmaceuticals, Inc.

Index	-	P/E	-	EPS (ttm)	-1.10	Insider Own	15.53%	Shs Outstand	41.02M	Perf Week	-5.19%
Market Cap	203.95M	Forward P/E	-	EPS next Y	-1.60	Insider Trans	0.00%	Shs Float	34.55M	Perf Month	25.13%
Income	-45.00M	PEG	-	EPS next Q	-0.35	Inst Own	77.20%	Short Float / Ratio	0.46% / 0.91	Perf Quarter	-5.92%
Sales	-	P/S	-	EPS this Y	79.00%	Inst Trans	6.22%	Short Interest	0.16M	Perf Half Y	-21.99%
Book/sh	4.37	P/B	1.13	EPS next Y	-21.20%	ROA	-22.50%	Target Price	14.57	Perf Year	38.48%
Cash/sh	3.39	P/C	1.45	EPS next 5Y	9.70%	ROE	-23.40%	52W Range	3.16 - 10.97	Perf YTD	-8.70%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-55.06%	Beta	-
Dividend %	-	Quick Ratio	16.40	Sales past 5Y	-	Gross Margin	-	52W Low	55.77%	ATR	0.53
Employees	39	Current Ratio	16.40	Sales Q/Q	-	Oper. Margin	-	RSI (14)	49.39	Volatility	7.68% 13.54%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-22.20%	Profit Margin	-	Rel Volume	0.37	Prev Close	4.94
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 09 BMO	Payout	-	Avg Volume	175.41K	Price	4.93
Recom	1.60	SMA20	-5.82%	SMA50	11.24%	SMA200	-13.09%	Volume	64,974	Change	-0.20%

Date	Action	Analyst	Rating Change	Price Target Change
May-18-23	Initiated	Cantor Fitzgerald	Overweight	$13
Jul-15-22	Initiated	BTIG Research	Buy	$15
Jun-30-22	Initiated	H.C. Wainwright	Buy	$15
Jan-21-22	Upgrade	BofA Securities	Neutral → Buy	$16 → $14
Jul-26-21	Initiated	UBS	Buy	$27
Jul-26-21	Initiated	Stifel	Buy	$27
Jul-26-21	Initiated	Credit Suisse	Outperform	$26
Jul-26-21	Initiated	BofA Securities	Neutral	$20

May-16-23 12:41PM	Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q1 2023 Earnings Call Transcript (Insider Monkey) -9.52%
May-09-23 07:00AM	Acumen Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Highlights (GlobeNewswire) +18.14%
May-04-23 04:01PM	Acumen Pharmaceuticals to Participate in 2023 Bank of America Healthcare Conference (GlobeNewswire)
May-02-23 04:01PM	Acumen Pharmaceuticals to Report First Quarter Financial Results on May 9, 2023 (GlobeNewswire) -6.09%
Apr-09-23 08:57AM	Institutions own 26% of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) shares but private equity firms control 42% of the company (Simply Wall St.)
07:30AM	Loading…
Mar-29-23 07:30AM	Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-28-23 08:00AM	Acumen Pharmaceuticals Presents in vitro Human Neuron Model for Evaluating Binding of Amyloid Beta Oligomers in Alzheimers Disease (GlobeNewswire)
Mar-27-23 07:00AM	Acumen Pharmaceuticals Reports Financial Results for Full Year Ended December 31, 2022 and Business Highlights (GlobeNewswire) +7.40%
Mar-22-23 04:01PM	Acumen Pharmaceuticals to Participate in Stifel 2023 Virtual CNS Days (GlobeNewswire) +5.15%
Mar-20-23 04:01PM	Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2022 Financial Results on March 27, 2023 (GlobeNewswire)
Mar-08-23 04:01PM	Acumen Pharmaceuticals to Participate in the Needham Neuroscience Forum (GlobeNewswire)
Feb-15-23 12:07PM	Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Feb-13-23 08:00AM	Acumen Pharmaceuticals Completes Enrollment in Phase 1 Trial of ACU193, First Monoclonal Antibody Developed to Selectively Target Toxic A Oligomers in Patients with Early Alzheimers Disease (GlobeNewswire)
Jan-06-23 09:40AM	Is Novo Nordisk (NVO) Stock Outpacing Its Medical Peers This Year? (Zacks) -8.55%
Jan-04-23 08:00AM	Acumen Pharmaceuticals Appoints Derrell Porter, M.D., to its Board of Directors (GlobeNewswire)
06:02AM	Loading…
Dec-29-22 06:02AM	Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q3 2022 Earnings Call Transcript (Insider Monkey) +11.64%
Nov-14-22 04:01PM	Acumen Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business Highlights (GlobeNewswire) -9.71%
Nov-09-22 04:01PM	Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference (GlobeNewswire) -7.45%
Nov-07-22 04:01PM	Acumen Pharmaceuticals to Report Third Quarter 2022 Financial Results on Nov. 14, 2022 (GlobeNewswire)
Nov-01-22 08:00AM	Acumen Publishes Phase 1 Trial Design and Clinical Development Plan for ACU193, an Anti-Amyloid Beta Oligomer Antibody for Alzheimers Disease (GlobeNewswire)
Oct-24-22 08:00AM	Acumens ACU193, an Anti-Amyloid Beta Oligomer Antibody, Granted FDA Fast Track Designation for Alzheimer's Disease (GlobeNewswire)
Sep-08-22 12:44PM	We Think Acumen Pharmaceuticals (NASDAQ:ABOS) Can Afford To Drive Business Growth (Simply Wall St.)
Aug-15-22 11:00PM	Acumen Pharmaceuticals, Inc. (ABOS) Q2 2022 Earnings Call Transcript (Motley Fool)
04:05PM	Acumen Pharmaceuticals Reports Financial Results for Second Quarter 2022 and Business Highlights (GlobeNewswire)
Aug-08-22 04:15PM	Acumen Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 15, 2022 (GlobeNewswire)
Aug-01-22 10:30AM	Acumen presents poster describing method to standardize amyloid beta oligomer assays supporting therapeutic development for early Alzheimers disease (GlobeNewswire) -8.09%
Jul-26-22 04:15PM	Acumen Pharmaceuticals to Participate in Upcoming Investor and Scientific Conferences (GlobeNewswire)
Jun-08-22 08:00AM	Hopeful week for insiders who might be regretting buying US$5.7m of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) stock earlier this year (Simply Wall St.)
May-16-22 10:00PM	Acumen Pharmaceuticals, Inc. (ABOS) Q1 2022 Earnings Call Transcript (Motley Fool)
04:05PM	Acumen Pharmaceuticals Reports Financial Results for First Quarter 2022 and Business Highlights (GlobeNewswire)
05:08PM	Loading…
May-11-22 05:08PM	Acumen Pharmaceuticals to Report First Quarter 2022 Financial Results on May 16, 2022 (GlobeNewswire) -14.21%
Apr-27-22 08:00AM	Comprehensive Analysis in Frontiers in Neuroscience Highlights Acumen Pharmaceuticals New Approach to Treating Alzheimer's Disease (GlobeNewswire)
Apr-02-22 12:00AM	Acumen Pharmaceuticals, Inc. (ABOS) Q4 2021 Earnings Call Transcript (Motley Fool)
Apr-01-22 05:01PM	We're Hopeful That Acumen Pharmaceuticals (NASDAQ:ABOS) Will Use Its Cash Wisely (Simply Wall St.)
Mar-28-22 04:05PM	Acumen Pharmaceuticals Reports Financial Results for Full Year Ended December 31, 2021 and Business Highlights (GlobeNewswire) -9.34%
Mar-16-22 04:15PM	Acumen Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on March 28, 2022 (GlobeNewswire) +11.72%
Dec-30-21 04:16AM	Bullish Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) insiders filled their treasuries with US$5.7m worth of stock over last year (Simply Wall St.)
Nov-25-21 07:35AM	15 Pharmaceutical Stocks to Buy According to Peter Kolchinskys RA Capital (Insider Monkey)
Nov-15-21 08:00AM	Acumen Pharmaceuticals Reports Financial Results for Third Quarter 2021 and Business Highlights (GlobeNewswire) -8.49%
Nov-08-21 08:00AM	Acumen Pharmaceuticals to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-02-21 08:00AM	Acumen Pharmaceuticals to Present Clinical Trial Design for INTERCEPT-AD, the Phase 1 Placebo-Controlled, Single- and Multiple-Dose Clinical Trial of ACU193, at 2021 Clinical Trials on Alzheimers Disease (CTAD) Conference (GlobeNewswire)
Oct-07-21 08:00AM	Acumen Announces First Patient Dosed in a Phase 1 Clinical Trial of ACU193, a Monoclonal Antibody that Selectively Targets Toxic A Oligomers for the Treatment of Early Alzheimers Disease (GlobeNewswire)
Oct-01-21 06:05AM	Companies Like Acumen Pharmaceuticals (NASDAQ:ABOS) Are In A Position To Invest In Growth (Simply Wall St.)
Aug-16-21 04:05PM	Acumen Pharmaceuticals Reports Financial Results for Second Quarter 2021 and Business Highlights (GlobeNewswire)
Jul-23-21 07:13PM	Landmark Infrastructure, CVRx See Activist Action (Barrons.com)
Jul-01-21 05:02PM	Krispy Kreme IPO Gains Nearly 24% in Busy Week for Deals (Barrons.com)
11:14AM	Acumen Pharmaceuticals shares soar 25% in trading debut (MarketWatch)
Jun-30-21 10:44PM	Acumen Pharmaceuticals Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Zuga Matt	CFO and Chief Business Officer	Dec 29	Option Exercise	1.19	50,000	59,500	76,187	Jan 03 05:23 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ABOS | Acumen Pharmaceuticals, Inc.

Upgrade your FINVIZ experience